Skip to main content

Table 3 Adverse drug reactions

From: Results of sub-analysis of a phase 2 study on trabectedin treatment for extraskeletal myxoid chondrosarcoma and mesenchymal chondrosarcoma

  

N = 5

  

≥G1

≥G3

  

n (%)

n (%)

Any adverse drug reactions

5 (100.0)

5 (100.0)

Clinical findings

  
 

Nausea

4 (80.0)

2 (40.0)

 

Malaise

4 (80.0)

0 (0.0)

 

Vomiting

3 (60.0)

0 (0.0)

 

Decreased appetite

3 (60.0)

0 (0.0)

 

Constipation

3 (60.0)

0 (0.0)

 

Oedema peripheral

3 (60.0)

0 (0.0)

 

Anaemia

2 (40.0)

2 (40.0)

 

Oral discomfort

2 (40.0)

0 (0.0)

 

Stomatitis

2 (40.0)

0 (0.0)

 

Pyrexia

2 (40.0)

0 (0.0)

 

Dysgeusia

2 (40.0)

0 (0.0)

 

Headache

2 (40.0)

0 (0.0)

Abnormal laboratory values

  
 

Neutrophil count decreased

5 (100.0)

5 (100.0)

 

Platelet count decreased

4 (80.0)

1 (20.0)

 

White blood cell count decreased

4 (80.0)

4 (80.0)

 

Alanine aminotransferase increased

2 (40.0)

2 (40.0)

  1. Adverse drug reactions occurring in ≥ 2 subjects are shown
  2. Grade was assessed according to Common Terminology Criteria for Adverse Events (CTCAE) version 4.03